Health Equity and Access to Medicines
Increasing access to quality medicines is essential to improving people’s health - especially for the millions of patients who continue to face barriers to care.
Getting medicine or care shouldn’t depend on where you live or what you can afford. But for too many people, it does. About one in three people around the world don’t have reliable access to medicines and other essential healthcare.01
We are helping to change that.
Our innovative medicines help address unmet health needs, and our generic and biosimilar medicines offer more affordable options for patients around the world.
Through our eight Access to Medicines programs, we help even more people get the medicines they need, in partnership with trusted local organizations.
Between 2021–2025, we donated ~2B units of medicine - representing an estimated $3.5B in value. In 2025, our product donations reached ~8M patients.
While we are a medicines company, we know medicines are just one aspect of how people get and stay healthier. We train healthcare professionals, improve diagnosis and screening and help people understand health information so patients can get better treatment, faster.
Since 2022, we have reached ~500,000 people through these efforts.
When a disaster strikes, timing is everything. We work with trusted partners to get treatments where they’re needed, quickly. In partnership with Direct Relief, our Strategic Emergency Stockpile keeps a steady supply of essential medicines so they’re ready in times of crisis.
During Hurricane Melissa and the California wildfires, Teva donated over 9M doses for conditions like diabetes, cardiovascular disease and infections.
We get medicines approved in places that need them most
Making medicines available depends on them being approved by local authorities. We work to get more medicines approved in low- and middle-income countries (LMICs) so more patients can get essential treatments—especially for noncommunicable diseases, which are among the leading causes of death worldwide.
From 2022 to 2025, we completed 83 regulatory submissions for essential medicines in LMICs (177% more than 2017-2020).
To make sure our medicines better reflect real needs and experiences, we:
• Design clinical trials with input from patients and caregivers
• Include people from a wide range of backgrounds
• Use flexible approaches, like home visits and remote technologies
• Work closely with sites to improve patient awareness and communication
In 2025, 100% of new early innovative clinical trials received insights from patients or caregivers regarding the clinical trial design or journey.
Teva Increasing Access to Medicines
Getting Medicines to All Who Need Them
Our Access to Medicines Programs
Global HOPE (Sub-Saharan Africa)
Donations
Malawi, Uganda, Botswana, Tanzania and Rwanda
Sub-Saharan Africa faces a childhood cancer crisis, driven in part by limited access to pediatric cancer care. We partner with Global HOPE (Hematology-Oncology Pediatric Excellence) to help children with cancer and blood disorders get the treatment they need, while also strengthening local care through training and early diagnosis.
Our Impact (since 2022):
- ~5.4M doses of medicine donated, worth $38M+
- ~138,100 children reached with medicines
- ~3,500 beneficiaries of training and diagnosis programs
Breast Cancer Care (Ghana)
Donations
Ghana
Breast cancer is the most common cancer among women in Ghana, and many patients face barriers to early diagnosis and treatment. Through our long-term partnership with Breast Care International, we expand access to care by providing treatments, raising awareness and strengthening local capacity for screening.
Our Impact (since 2022):
- ~1.6M doses of medicine donated, worth ~$7.9M
- ~5,300 patients reached with medicines
- ~44,000 beneficiaries (e.g., patients, healthcare professionals) reached
Community Routes: Mental Health Care (US)
Donations
US
Many people in the U.S. face barriers to accessing mental health care. In partnership with Direct Relief and the National Association of Free & Charitable Clinics (NAFC), we donate depression and anxiety medications and grant funding to free clinics for uninsured, underserved populations, aiming to remove barriers to mental health care and improve health equity.
In early 2025, Teva made an additional commitment of $2 million over two years and announced a new cohort of 11 grantees across Alabama, Mississippi and Texas to support behavioral health services.
Our Impact (since 2022):
- 43.9M+ doses of medicine donated,
worth over $26M - ~160,000 patients reached
- ~121,000 people reached through health
equity initiatives
Strategic Emergency Stockpile
Donations
Global
In emergencies, access to essential medicines can be critical. In partnership with Direct Relief, we maintain a reserve of medicines that can be deployed quickly to support patients and communities during crises.
Our Impact (since 2024):
- 11.6M+ doses of medicine donated,
worth $15.7M+ - ~116,200 people reached
Chronic Disease Care (El Salvador)
Donations
El Salvador
People with low income in El Salvador often have limited access to basic healthcare, while chronic conditions continue to rise. In partnership with Americares and FUSAL, we expand access to treatment through local clinics, focusing on conditions like cardiovascular and respiratory disease, diabetes and pain management.
Our Impact (since 2024):
- 671,800+ doses of medicine donated, worth $725K+
- ~13,000 patients reached
Friends for Health (Israel)
Donations
Israel
In Israel, patients in need often struggle to access essential treatments due to cost or gaps in insurance coverage. In partnership with Friends for Health (Haverim L’Refuah), we help expand access by providing donated medicines to underserved patients through a trusted local network.
Our Impact (2025):
- 500,000+ doses of medicine donated, worth ~$945K
- 5,000+ patients reached
Supporting Underserved Communities (Spain)
Social Business
Spain
Approximately 1.5 million people in Spain cannot afford prescription medicines and health products for chronic diseases. We support Banco Farmacéutico to increase access for underserved populations.
Our Impact (since 2023):
- 177,600+ doses of medicine supplied
- ~3,500 patients reached
Community-Based Care (France)
Social Business
France
In collaboration with Pharmacie Humanitaire Internationale, we supply medicine to charitable care centers that give medication, consultations and social services to underserved patients.
Our Impact (since 2023):
- 5.7M+ doses of medicine supplied
- ~180,000 patients reached
Progress Against Targets
| Target | Progress | Status |
|---|---|---|
| Increase the cumulative number of new regulatory submissions in low- and middle-income countries (LMICs) on the WHO Essential Medicines List (EML) across six key therapeutic areas (TAs)1 by 150% from 2022-2025 (vs. 2017-2020) 02 | 83 cumulative (increased by 177% vs. 2017-2020) | Surpassed |
| New target: Increase the cumulative number of new regulatory submissions LMICs on the WHO EML across six key TAs 02 by 220% from 2022–2027 (vs. 2017–2020) 04 | 83 cumulative submissions (increased by 177% vs. 2017-2020) | On track |
| Increase access to medicines program product volume by 150% in 2025 (vs. 2020) through four access to medicines programs, including donations and social business, in LMICs on WHO EML across six key TAs 02 03 | 6.7M single unit doses provided (increased by 1242% vs. 2020) | Surpassed |
| New target: Increase the cumulative number of underserved patients reached with product through access initiatives to at least 1M from 2023-2029 | 537,746 patients reached with our product (54% to target) | On track |
| Increase the cumulative number of beneficiaries of health systems-strengthening and capacity-building initiatives in support of underserved populations by 200% by 2026 (vs. cumulative 2022-2023 baseline) | 470,709 beneficiaries reached (increased by 1533% vs. 2022-2023) | Surpassed |
| Incorporate a patient-centric approach in 100% of clinical trials for innovative products by 2030, which will help enable more equitable access to medicines | 100% of clinical trials for innovative products initiated in 2025 incorporated a patient centric approach | On track |
Footnotes
-
Back to contents.
Essential Medicines and Pharmaceutical Policies, Strategy/Policy: Access. World Health Organization: https://www.emro.who.int/essential-medicines/strategy-access/
-
Back to contents.
Therapeutic areas for submissions include: cardiovascular diseases, pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care. Therapeutic areas for volumes include: cardiovascular diseases, adult and pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care.
-
Back to contents.
Target is part of sustainability-linked bond.
-
Back to contents.
Target is related to syndicated sustainability-linked revolving credit facility.